hit counter
Alexion Pharmaceuticals, Inc. (ALXN) Stock News Sentiment & Price - Sentifly
ALXN - Sentifly



Your watchlist is empty. Go add some tickers to it!

Alexion Pharmaceuticals, Inc. (ALXN)

ALXN Price and Sentiment
Positive, Negative
Loading chart...
ALXN Latest news
Why Did AstraZeneca's Alexion Stop Amyotrophic Lateral Sclerosis Trial?
2021-08-20 09:53

AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to lack of efficacy in a late-stage trial. Following an interim analysis, Alexion says it will scrap a Phase 3 study testing the long-acting C5 inhibitor Ultomiris as a treatment for amyotrophic lateral sclerosis.

Proactive Investors
AstraZeneca eyes big jump in revenue after Alexion acquisition
2021-07-29 05:07

AstraZeneca PLC has announced higher full-year guidance to include the newly acquired Alexion, after the transaction was completed last week. The pharma giant expects total revenue to jump 21-22%, with core earnings per share (EPS) from US$5.05 to US$5.40.

Proactive Investors
AstraZeneca says Alexion receives recommendation to use rare blood disorder drug in kids
2021-07-26 03:09

AstraZeneca PLC (LON:AZN) announced that Alexion's Ultomiris has been recommended for marketing authorisation in the EU for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria (PNH). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on interim results from the Phase III clinical trial in children and teens with PNH.

Zacks Investment Research
Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?
2021-07-22 16:47

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research
ALXN vs. TECH: Which Stock Is the Better Value Option?
2021-07-21 13:09

ALXN vs. TECH: Which Stock Is the Better Value Option?

Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms
2021-07-20 14:37

Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year. The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing, a whopping 48% increase over the same period in 2020.

The Motley Fool
With the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?
2021-07-17 06:48

With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
2021-07-16 16:19

What did the stock market do today? It saw Moderna reach a major index, it saw Americans spending big, and it saw Biden targeting China.

Zacks Investment Research
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study
2021-07-16 15:28

Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.

Loading more news...